January 17, 2022

Volume XII, Number 17

Advertisement
Advertisement

January 15, 2022

Subscribe to Latest Legal News and Analysis

January 14, 2022

Subscribe to Latest Legal News and Analysis

Optis Puts Apple’s Feet to the UK Fire: Commit to FRAND or Be Snuffed Out

Recent developments indicate that the UK is a favorable jurisdiction that owners of standard essential patents (“SEP”) can leverage to obtain appropriate SEP rates from what would otherwise be unwilling licensees.  Demonstrating the point, a recent order from Justice Meade of the High Court in the sprawling Pan Optis/Unwired Planet SEP dispute with Apple provides an outline to the UK’s approach to handling SEP implementers who are unwilling to commit to court-determined FRAND licenses.   In a lengthy decision, issued September 27, 2021, Justice Meade essentially gave Apple two choices: (1) commit, now, to taking a FRAND license with terms to be decided at a subsequent trial taking place in 2022; or (2) be enjoined from the UK market until resolution of the FRAND trial and acceptance of the terms that issue.  Importantly, Justice Meade issued this ultimatum even though Apple has threatened to abandon the UK market rather than agree to any global FRAND rate set by the UK courts.

Background

Optis and Apple have long been engaged in a global dispute over Optis’ SEP patent portfolio related to the Long-term Evolution (LTE) standard for wireless telecommunications.  This past August, a jury from the Eastern District of Texas awarded Optis $300 million in damages after Apple was found to infringe Optis’ SEP patents.  This award was the result of a retrial ordered by U.S. District Judge Rodney Gilstrap, after finding the jury’s previous award of $506 million may not have been in line with Optis’ responsibility to license the patents on FRAND terms.  Apple will certainly appeal this second seven figure jury award.

Meanwhile, across the pond in the UK, the parties have been embroiled in four technical trials to determine the validity of Optis’ asserted patents and Apple’s infringement.  (The UK system typically deals with issues of validity and infringement on a patent-by-patent basis in technical trials, while issues such as FRAND terms and competition law are dealt with separately).

In June of 2021, at the conclusion of one of technical trials, one of Optis’ patents was found to be valid, essential, and infringed by Apple. A FRAND trial is slated to commence in June 2022 to determine the terms of global FRAND license, but Optis sought an injunction in the interim because of Apple’s unwillingness to commit to the resulting license to be determined by the court.  As such, the UK judge, Justice Meade, held a hearing on whether Apple was a willing or unwilling licensee.

The Dispute

Optis argued that Apple’s refusal to commit to accepting the court’s FRAND license determination made Apple an unwilling licensee and therefore not entitled to the benefits of ETSI protection.  Optis argued that Apple’s refusal meant that it lost the right to ultimately take a FRAND license and alternatively that a FRAND injunction should issue in the interim until Apple did accept the terms.  On the other hand, Apple argued that it should be able to see the terms of FRAND license prior to committing to them.

The Decision

The court found that Apple’s refusal to undertake any commitment to the FRAND license on the terms decided at a subsequent trial made it an unwilling licensee. The court was unmoved by Apple’s argument that mere “happenstance” created the gap between the technical trials and the FRAND trial and stated that “If [Apple] wanted earlier certainty about FRAND terms it could have argued for something else.”  The court, however, rejected Optis’ request for an unqualified injunction finding that Apple did not permanently foreclose its right to take a FRAND license.

The court concluded that “Apple can only rely on Optis’ undertaking to ETSI if it (Apple) commits to enter into the FRAND licence determined at [at the FRAND trial]” and gave Apple “a short time to consider whether it wishes to commit in that way, or offer some other undertaking.”

Of particular note in this decision is the court’s detailed description of the SEP and FRAND legal landscape in the UK and abroad, which will provide fodder for analysis for quite a while.

The Takeaway

Apple is facing down an injunction for all LTE-compliant products in the UK unless it commits, blindly, to the FRAND rate to be set in 2022.  While Apple has stated that it may abandon the UK market rather than pay what it considers to be a commercially unreasonable FRAND rate, Apple’s feet are now being put to the fire.  The UK’s approach to Apple here is instructive, in that Justice Meade is signaling to SEP implementers that they must agree to FRAND terms (and by implication demonstrate conclusively their status as a willing licensee) or face severe consequences.  Failure to agree in advance to FRAND terms may further demonstrate how an implementer is an unwilling licensee.  While other jurisdictions such as Germany already have demonstrated a willingness to enjoin SEP infringers, recent developments have indicated that patent injunctions in Germany may be restricted in the future, though that is still to be seen.  This decision may leave the UK as a prime destination in Europe for SEP holders to leverage their best patents against implementers.  We will see what the United States courts do in the wake of the UK decision, especially in light of the HTC v. Ericsson Fifth Circuit decision finding that Ericsson complied with FRAND.  Right now though, both the United States and the UK look like they are clarifying the law and, at least as recent cases indicate, are moving to be favorable jurisdictions for SEP holders to vindicate their rights when faced with unwilling licensees. 

*The case is Optis Cellular Technology, LLC, et al. v. Apple Retail UK Limited, et al. 2021 EWHC 2564 (Pat) Case No. HP-2019-000006.

©1994-2022 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. All Rights Reserved.National Law Review, Volume XI, Number 277
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement

About this Author

Michael Renaud IP Litgation Attorney Mintz Levin
Member / Chair, Intellectual Property Division

Michael is a highly regarded intellectual property litigator and patent strategist who helps clients protect and generate revenue from their patent holdings. Intellectual Asset Magazine has repeatedly recognized him in its select IAM Patent 1000 and IAM Patent Strategy 300 publications. Clients rely on his counsel regarding sensitive licensing agreement negotiations, acquisitions, and other technology transactions. He leads a team known for its ability to translate complex technology and its value to non-technical professionals — in court and business negotiations.

Michael is...

617-348-1870
Daniel B. Weinger Patent Litigation Attorney Mintz Law Firm
Member

Daniel's practice in intellectual property focuses on patent litigation, both at the International Trade Commission and the Federal District Courts. Daniel has participated in all phases of patent litigation, including active engagement in multiple evidentiary hearings at the International Trade Commission. He has done work in a variety of technology areas, including computer software, software architecture, GPS, network devices, semiconductors, converged devices, and LED lighting.

Prior to joining Mintz Levin, Daniel worked as a database...

617-348-1629
James Thomson IP Litigation Lawyer Mintz Levin Cohn Ferris Glovsky and Popeo PC
Associate

James is an experienced intellectual property litigator with significant courtroom and trial experience in federal courts. He handles all aspects of litigation, including e-discovery, motion practice, taking and defending depositions, and trial preparation. He has particular experience handling damages assessments involving complex technologies.

James represents clients in patent and trademark infringement cases and in trade secrets matters, with a focus on high technology innovations. He also has experience representing clients in the biotechnology, pharmaceutical, and medical...

617-348-3098
Advertisement
Advertisement
Advertisement